Shares of Acumen Pharmaceuticals, Inc. (ABOS) surged over 100 percent in the early morning trade on Monday after the firm declared positive top line results from the Phase 1 INTERCEPT-AD trial of ACU193, the first clinical-stage amyloid beta oligomer or AßO targeting antibody therapy in early Alzheimer's disease.
from RTT - Before the Bell https://ift.tt/vr019MA
via IFTTT
No comments:
Post a Comment